Headline data from QUIET-1 confirm lack of efficacy of AUT00063 in the treatment of people with mild-to-moderate tinnitus AUT00063 was safe and well tolerated Trial of AUT00063 in age-related hearing…
Read More
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing loss and other serious brain disorders, today announced the start of Phase I clinical evaluation…
Read More
Autifony Therapeutics has now completed a planned interim analysis on the QUIET-1 tinnitus clinical trial with AUT00063. This analysis was conducted to check for evidence of treatment efficacy and to…
Read More
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that Dr John Hutchison has joined the company as Chief Medical Officer,…
Read More
